One patient received CD19 targeted CAR‐T due to relapsed DLBCL 30 months ago and reached CR, but unfortunately, the patient relapsed 18 months ago, so the patient received a second time CD19 targeted CAR‐T infusion but only best response of PD had been reached and rapidly progressed again. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.